NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Epic Sciences today announced an agreement with Laboratory Corporation of America aimed at speeding up sample processing for Epic's technology in support of European clinical trials.

LabCorp's Central Laboratory in Mechelen, Belgium will process samples for Epic's clinical trial partners and customers as part of the deal. The samples will then be sent to Epic's laboratory in La Jolla, Calif. for downstream detection and molecular characterization of CTCs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.